Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$22.19M-130%-$23.25M-27.2%-$17.75M-41.4%-$52.62M-261%$73.02M+499%
$1K-98.2%$1K-97.9%$5.6K-88.0%$15.3K-69.2%$57K+14.0%
$2.19M+30.5%$2.39M+28.8%$2.72M+6.3%$3.09M+8.7%$1.68M-53.2%
$0-100%$0-$177K$0$87.44M
$0-100%$1M+280%
-$0+100%-$170K+65.3%
-$3.49M-458%$4.67M$985K+116%-$2.71M$975K+114%
-$163K-43.0%$880K+865%-$114K+17.4%
$0+100%-$202K
$0+100%-$89K+29.4%
-$22.21M-87.2%-$17.23M-14.5%-$15.38M+2.0%-$52.96M-478%-$11.86M+39.6%
$0-100%$1K-99.8%$551K-25.4%
$19.19M$22.92M$93.56M+842%$32.22M+70.4%$0-100%
$38.62M+163%$39.76M+199%$2M-86.9%$3.39M-78.7%$14.69M-22.4%
$0-100%$101.36M
$19.43M-83.2%$16.85M+28.3%-$91.63M-1,902%$115.5M+994%
$0-100%$5K$21K
$0-100%$25K-52.8%$95.2M+952,110%
-$2.78M-101%$198.84M+2,283%
$347K+1,926%$831K+354%$717K+132%-$2K-101%-$19K-105%
$1K-98.2%$5.6K-88.0%$15.3K-69.2%$57K+14.0%
$0-100%$0-$177K$0$87.44M
$0+100%-$89K+29.4%
-$1.47M-92.2%$375K+280%$965K+639%-$141K+90.4%-$765K+19.7%
$0-100%$74K-35.7%
$0-100%$101.36M
$38.62M+163%$39.76M+199%$2M-86.9%$3.39M-78.7%$14.69M-22.4%
$0-100%$803K$4.82M
$0-100%$100M
$30K-82.0%$167K
$0+100%-$89K+29.4%
$0-100%$632K
-$22.21M-78.9%-$17.23M-13.1%-$15.38M+3.1%-$52.96M-446%-$12.42M+39.1%
-$22.21M-78.9%-$17.23M-13.1%-$15.38M+3.1%-$52.96M-446%-$12.42M+39.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Whitehawk Therapeutics, Inc. Common Stock generate?
Whitehawk Therapeutics, Inc. Common Stock (WHWK) generated -$107.8M in operating cash flow over the trailing twelve months.
What is Whitehawk Therapeutics, Inc. Common Stock's free cash flow?
After $738.0K of capital expenditures, Whitehawk Therapeutics, Inc. Common Stock's free cash flow was -$107.8M over the trailing twelve months, down 102.5% year over year.
Where does Whitehawk Therapeutics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.